Talaporfin Sodium as a Clinically Translatable Radiosensitizer in Radiodynamic Therapy
Biomolecules · 2025
DOI: 10.3390/biom15121748 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biomolecules, 2025. Verfasst von Junko Takahashi und 6 weiteren Autor:innen. Beteiligte Einrichtung: Graduate School of Information, Production and Systems, Waseda University, Kitakyusyu, Fukuoka 808-0135, Japan. Hauptthemen laut MEDLINE: Radiation-Sensitizing Agents, Porphyrins, Pancreatic Neoplasms. Die Arbeit nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: The Japan Agency for Medical Research and Development (AMED) and the Center for Clinical and Translational Research of Kyushu University, Meiji Seika Pharma Co., Ltd., the Japan Agency for Medical Research and Development.
Abstract (Originalsprache)
Talaporfin sodium (mono-L-aspartyl chlorin e6; NPe6), a second-generation photosensitizer, is clinically used in photodynamic therapy (PDT). It accumulates preferentially in tumors and exhibits deep tissue penetration, rapid systemic clearance, and minimal photosensitivity. However, treatment of deep-seated malignancies remains challenging. Here, we demonstrate that talaporfin sodium undergoes physicochemical reactions with X-rays to generate reactive oxygen species, a mechanism analogous to that of 5-aminolevulinic acid (5-ALA)-induced protoporphyrin IX in radiodynamic therapy (RDT). To evaluate its therapeutic efficacy, we employed a pancreatic cancer xenograft model using MIA PaCa-2 cells in mice. Talaporfin sodium was administered intravenously 2 h before X-ray exposure, followed by fractionated X-ray irradiation (3 Gy daily for 3 consecutive days). Talaporfin-mediated RDT significantly inhibited tumor growth compared with radiation therapy alone. Furthermore, an exploratory RNA-seq analysis of xenografts revealed transcriptional signatures of stress and immune activation, suggesting that talaporfin-mediated RDT enhances oxidative and immunogenic responses within the tumor microenvironment. These findings highlight the potential of talaporfin sodium as a clinically translatable radiosensitizer for RDT, offering a promising strategy for the treatment of deep-seated cancers such as pancreatic carcinoma.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Graduate School of Information, Production and Systems, Waseda University, Kitakyusyu, Fukuoka 808-0135, Japan.
- Department of Neurosurgery, University of Occupational and Environmental Health, Kitakyushu, Fukuoka, 807-8555, Japan.
ORCID-Profile: Junko Takahashi, Kohei Suzuki, Shohei Nagasaka
Förderung
- The Japan Agency for Medical Research and Development (AMED) and the Center for Clinical and Translational Research of Kyushu University
- Meiji Seika Pharma Co., Ltd.
- the Japan Agency for Medical Research and Development
Zitieren
APA
Takahashi, J., Yamamoto, J., Suzuki, K., Nagasaka, S., Yang, K., Zhao, H., & Yamaoka, T. (2025). Talaporfin Sodium as a Clinically Translatable Radiosensitizer in Radiodynamic Therapy. Biomolecules. https://doi.org/10.3390/biom15121748
Vancouver
Takahashi J, Yamamoto J, Suzuki K, Nagasaka S, Yang K, Zhao H, et al. Talaporfin Sodium as a Clinically Translatable Radiosensitizer in Radiodynamic Therapy. Biomolecules. 2025. doi:10.3390/biom15121748
BibTeX
@article{Takahashi2025,
author = {Takahashi, Junko and Yamamoto, Junkoh and Suzuki, Kohei and Nagasaka, Shohei and Yang, Kaizhen and Zhao, Haobo and Yamaoka, Teppei},
title = {Talaporfin Sodium as a Clinically Translatable Radiosensitizer in Radiodynamic Therapy},
journal = {Biomolecules},
year = {2025},
doi = {10.3390/biom15121748}
}
EUVIMED